

Number of new episodes of selected diagnoses by gender and age group, Northern Ireland, 2003-2013

		2003			2004			2005			2006			2007			2008			2009			2010			2011			2012			2013			
		M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total	M	F	Total				
Chlamydia	<16	0	7	7	0	13	13	0	9	9	*	*	22	*	*	11	*	*	13	0	8	8	*	*	11	0	9	9	0	*	*	*			
	16-19	81	180	261	72	206	278	75	215	290	87	220	307	115	206	321	93	243	336	113	236	349	105	192	297	104	191	295	85	173	258	84	170	254	
	20-24	248	294	542	326	333	659	334	396	730	445	458	903	375	342	717	477	385	862	447	327	774	423	338	761	424	374	798	387	315	702	385	365	750	
	25-34	236	151	387	247	159	406	303	184	487	362	239	601	365	205	570	371	220	591	416	201	617	373	220	593	390	191	581	360	210	570	355	191	546	
	35-44	60	26	86	46	32	78	54	38	92	80	39	119	65	36	101	76	27	103	81	39	120	96	28	124	71	20	91	73	28	101	73	28	101	
	45+	20	5	25	12	7	19	17	6	23	*	*	27	*	*	23	*	*	41	33	5	38	*	*	46	47	9	56	35	*	*	8	*		
	Total	645	663	1,308	703	750	1,453	783	848	1,631	993	986	1,979	938	805	1,743	1,050	896	1,946	1,090	816	1,906	1,036	796	1,832	1,036	794	1,830	940	736	1,676	930	769	1,699	
	% in MSM	4%			4%			7%			6%			4%			4%			11%			14%			15%			10%			12%			
Gonorrhoea^	<16	0	0	0	0	*	*	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	*	*	*	0	*	*	*	*	*	*		
	16-19	8	8	16	17	8	25	*	*	17	*	*	15	27	7	34	15	5	20	19	8	27	12	9	21	17	15	32	*	22	*	46	42	88	
	20-24	45	10	55	32	5	37	47	13	60	58	17	75	44	7	51	56	10	66	36	15	51	61	13	74	87	38	125	116	43	159	116	63	179	
	25-34	42	6	48	*	*	49	*	*	58	55	7	62	*	*	49	58	13	71	69	8	77	51	6	57	93	19	112	122	35	157	141	43	184	
	35-44	*	*	28	*	*	10	*	*	38	*	*	32	*	*	21	*	*	45	*	*	16	30	*	*	*	*	*	40	*	*	44	48	7	55
	45+	*	*	7	*	*	*	*	*	9	*	*	11	17	0	17	*	*	24	*	*	9	18	*	*	*	*	*	*	38	*	*	*	*	
	Total	127	27	154	105	19	124	162	20	182	163	32	195	155	17	172	194	32	226	148	32	180	172	32	204	259	77	336	344	107	451	380	157	537	
	% in MSM	31%			23%			40%			24%			29%			29%			29%			34%			56%			65%			46%			
Syphilis	<16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	16-19	0	0	0	0	0	0	*	0	*	0	*	*	*	0	*	*	0	*	0	0	0	0	*	*	*	*	*	*	*	0	*	*		
	20-24	*	0	*	5	5	10	5	0	5	*	*	13	5	0	5	*	*	10	*	*	*	*	*	12	5	0	5	15	0	15	11	*	*	
	25-34	5	0	5	*	*	11	*	*	9	10	0	10	*	*	9	*	*	10	*	*	11	18	0	18	11	0	11	18	0	18	17	*	*	
	35-44	*	0	*	*	*	15	12	0	12	*	0	*	*	0	*	*	0	*	9	0	9	6	0	6	*	*	*	8	0	8	8	0	8	
	45+	*	0	*	5	0	5	5	*	*	*	0	*	*	0	*	8	0	8	6	0	6	*	*	10	10	0	10	*	0	*	10	0	10	
	Total	10	0	10	31	10	41	29	5	34	*	*	30	*	*	22	*	*	33	*	*	29	*	*	46	*	*	38	50	0	50	48	*	52	
	% in MSM	50%			68%			66%			52%			52%			45%			78%			75%			78%			90%			83%			
Herpes	<16	*	*	*	0	*	*	*	*	*	0	*	*	0	*	*	0	*	*	0	*	*	0	*	*	0	6	6	0	5	5	0	0	0	
	16-19	5	31	36	*	*	34	6	39	45	7	33	40	5	44	49	11	58	69	7	43	50	10	57	67	5	71	76	10	39	49	7	47	54	
	20-24	14	53	67	28	56	84	20	64	84	21	60	81	32	53	85	11	78	89	38	56	94	42	87	129	30	68	98	32	75	107	33	71	104	
	25-34	23	49	72	25	39	64	28	46	74	39	52	91	27	55	82	38	47	85	41	80	121	52	79	131	56	65	121	50	72	122	55	85	140	
	35-44	14	21	35	11	22	33	8	19	27	18	21	39	26	13	39	8	19	27	17	32	49	36	21	57	24	26	50	18	18	36	21	32	53	
	45+	*	*	*	*	*	*	*	*	*	6	*	*	13	*	*	10	*	*	18	*	*	13	*	*	14	21	35	17	21	38	14	20	34	
	Total	60	166	226	69	153	222	66	172	238	91	183	274	103	173	276	78	218	296	121	225	346	153	258	411	129	257	386	127	230	357	130	255	385	
	% in MSM	5%			7%			8%			2%			4%			6%			7%			12%			11%			10%			23%			
Warts	<16	*	*	9	0	9	9	0	6	6	*	*	11	*	*	5	*	*	10	*	*	18	*	*	11	*	*	*	0	10	10	0	6	6	
	16-19	115	235	350	86	259	345	103	267	370	122	270	392	88	216	304	100	253	353	95	217	312	107	230	337	104	245	349	88	200	288	78	183	261	
	20-24	401	411	812	397	358	755	460	403	863	440	356	796	384	326	710	419	369	788	444	334	778	432	342	774	467	394	861	475	314	788	419	276	695	
	25-34	386	287	673	387	278	665	443	296	739	401	249	650	387	227	614	439	262	701	400	221	621	442	255	697	448	254	702	462	278	739	427	232	659	
	35-44	149	91	240	133	110	243	150	89	239	123	95	218	131	70	201	119	88	207	138	86	224	135	74	209	138	91	229	124	82	206	160	64	224	
	45+	*	*	92	56	28	84	52	37	89	*	*	89	*	*	95	*	*	84	*	*	133	*	*	98	*	*	154	99	58	157	89	55	144	
	Total	1,111	1,065	2,176	1,059	1,042	2,101	1,208	1,098	2,306	1,142	1,014	2,156	1,050	879	1,929	1,132	1,011	2,143	1,160	926	2,086	1,179	947	2,126	1,237	1,068	2,305	1,248	942	2,188	1,173	816	1,989	
	% in MSM	2%			3%			3%			2%			3%			2%			6%			8%			8%			10%			9%			
Total diagnoses		5,823	5,727	11,550	5,723	5,784	11,507	6,316	6,531	12,847	6,292	5,718	12,010	6,211	5,110	11,321	6,546	5,787	12,333	6,966	5,356	12,322	7,304	5,222	12,526	7,046	5,729	12,775	6,117	5,000	11,117	5,728	4,752	10,480	
Total workload		7,188	6,021	13,209	7,327	7,056	14,383	9,302	7,542	16,844	8,871	7,104	15,975	8,480	6,488	14,968	9,897	8,321	18,218	11,903	9,698	21,601	13,242	10,542	23,784	14,035	11,704	25,739	16,140	11,887	28,027	15,720	11,381	27,101	

Notes on using these tables:

% in MSM* represents the proportion of the total male diagnoses attributed to men who have sex with men (MSM)

^ It is likely that the use of more sensitive Nucleic Acid Amplification Tests (NAATs) has contributed to the increase in gonorrhoea.

* Data is confidential

Following recent ONS guidance on data disclosure, the rules on publication of STI data with small cell sizes have changed. Cells with a value between 1 and 4 will now be anonymised with an astrich. In addition, where the anonymised cell can be deduced from the totals, the next smallest cells will also be anonymised.

Definitions of selected conditions:

Chlamydia	uncomplicated genital chlamydial infection, KC60 code C4a, C4c
Gonorrhoea	uncomplicated gonorrhoea, KC60 code B1, B2
Syphilis	primary and secondary infectious syphilis, KC60 code A1, A2
Herpes	anogenital herpes simplex (first attack), KC60 code C10a
Warts	anogenital warts (first attack), KC60 code C11a
Total diagnoses	all diagnoses made, includes all A, B, C and E KC60 codes
Total workload	all workload not requiring a diagnoses, includes all D, P and S KC60 codes